HERMIEN CLYBURN: Open Payments
NPI 1588223861 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,856 in 148 payments from 26 companies in 2025. Trend: 2023 $1,082 · 2024 $3,268 · 2025 $2,856
Food & beverage: $2,856
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $532 |
| AstraZeneca Pharmaceuticals LP | 4 | $440 |
| Axsome Therapeutics, Inc. | 16 | $248 |
| Novartis Pharmaceuticals Corporation | 13 | $183 |
| Amgen Inc. | 17 | $181 |
| Lundbeck LLC | 9 | $173 |
| Janssen Pharmaceuticals, Inc | 9 | $170 |
| Novo Nordisk Inc | 10 | $162 |
| Lilly USA, LLC | 10 | $120 |
| Astellas Pharma US Inc | 5 | $86 |
Products named: FARXIGA, VRAYLAR, LEQVIO, VYEPTI, SPRAVATO, Auvelity, UBRELVY, Wegovy.
Industry payments across TX — which companies pay providers there.
